Bilaketaren emaitzak - Peter D. Eisenberg

  • Erakusten 1 - 14 emaitzak -- 14
Findu emaitzak
  1. 1
    Efficacy, safety and pharmacokinetics of palonosetron in patients receiving highly emetogenic cisplatin-based chemotherapy:a dose-ranging clinical study

    Efficacy, safety and pharmacokinetics of palonosetron in patients receiving highly emetogenic cisplatin-based chemotherapy:a dose-ranging clinical study nork Peter D. Eisenberg, F. Roy MacKintosh, Paul S. Ritch, Patricia A. Cornett, A. Macciocchi

    Argitaratua 2004
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  2. 2
    Improved prevention of moderately emetogenic chemotherapy‐induced nausea and vomiting with palonosetron, a pharmacologically novel 5‐HT<sub>3</sub> receptor antagonist

    Improved prevention of moderately emetogenic chemotherapy‐induced nausea and vomiting with palonosetron, a pharmacologically novel 5‐HT<sub>3</sub> receptor antagonist nork Peter D. Eisenberg, Jazmin Figueroa‐Vadillo, Rosalio Zamora, Veena Charu, Julio Hajdenberg, Alan Cartmell, A. Macciocchi, Steven M. Grunberg

    Argitaratua 2003
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  3. 3
    Adjuvant Therapy With the Monoclonal Antibody Edrecolomab Plus Fluorouracil-Based Therapy Does Not Improve Overall Survival of Patients With Stage III Colon Cancer

    Adjuvant Therapy With the Monoclonal Antibody Edrecolomab Plus Fluorouracil-Based Therapy Does Not Improve Overall Survival of Patients With Stage III Colon Cancer nork Anthony Fields, Alan Keller, Lee S. Schwartzberg, Stephen A. Bernard, Carl G. Kardinal, Alan F. Cohen, Joe Schulz, Peter D. Eisenberg, John Forster, Paul Wissel

    Argitaratua 2009
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  4. 4
    Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion

    Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion nork Lee S. Rosen, David Gordon, William Dugan, Pierre Major, Peter D. Eisenberg, Louise Provencher, Mary Kaminski, J. Simeone, John J. Seaman, Bee‐Lian Chen, Robert E. Coleman

    Argitaratua 2003
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  5. 5
    A Phase I Dose Escalation and Expansion Study of the Anticancer Stem Cell Agent Demcizumab (Anti-DLL4) in Patients with Previously Treated Solid Tumors

    A Phase I Dose Escalation and Expansion Study of the Anticancer Stem Cell Agent Demcizumab (Anti-DLL4) in Patients with Previously Treated Solid Tumors nork David C. Smith, Peter D. Eisenberg, Georgy M. Manikhas, Rashmi Chugh, Matthew A. Gubens, Robert Stagg, Ann M. Kapoun, Lu Xu, Jakob Dupont, Branimir I. Šikić

    Argitaratua 2014
    Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  6. 6
    Bemarituzumab With Modified Folfox6 For Advanced Fgfr2-Positive Gastroesophageal Cancer: Fight Phase Iii Study Design

    Bemarituzumab With Modified Folfox6 For Advanced Fgfr2-Positive Gastroesophageal Cancer: Fight Phase Iii Study Design nork Daniel V.T. Catenacci, Anteneh Tesfaye, M.A. Tejani, Eric Cheung, Peter D. Eisenberg, Aaron J. Scott, Clarence Eng, James Hnatyszyn, Neyssa Marina, Janine Powers, Zev A. Wainberg

    Argitaratua 2019
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  7. 7
    Efficacy and tolerability of aprepitant for the prevention of chemotherapy‐induced nausea and emesis over multiple cycles of moderately emetogenic chemotherapy

    Efficacy and tolerability of aprepitant for the prevention of chemotherapy‐induced nausea and emesis over multiple cycles of moderately emetogenic chemotherapy nork Jørn Herrstedt, Hyman B. Muss, David Warr, Paul J. Hesketh, Peter D. Eisenberg, Harry Raftopoulos, Steven M. Grunberg, Munir Gabriel, Anthony Rodgers, Carolyn M. Hustad, Kevin Horgan, Franck Skobieranda

    Argitaratua 2005
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  8. 8
    Randomised, phase II trial comparing oral capecitabine (Xeloda®) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclines

    Randomised, phase II trial comparing oral capecitabine (Xeloda®) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclines nork Denis Talbot, Vladimir Moiseyenko, Simon Van Belle, S.M. O'Reilly, Emilio Alba, Stephen P. Ackland, Peter D. Eisenberg, David Melnychuk, Tadeusz Pieńkowski, H-U Burger, Siobhan Laws, B Osterwalder

    Argitaratua 2002
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  9. 9
    Phase II Study of the Anti–Insulin-Like Growth Factor Type 1 Receptor Antibody CP-751,871 in Combination With Paclitaxel and Carboplatin in Previously Untreated, Locally Advanced, or Metastatic Non–Small-Cell Lung Cancer

    Phase II Study of the Anti–Insulin-Like Growth Factor Type 1 Receptor Antibody CP-751,871 in Combination With Paclitaxel and Carboplatin in Previously Untreated, Locally Advanced,... nork Daniel D. Karp, Luis Paz‐Ares, Silvia Novello, Paul Haluska, Linda L. Garland, Felipe Cardenal, L. Johnetta Blakely, Peter D. Eisenberg, Corey J. Langer, George R. Blumenschein, Faye M. Johnson, Stephanie Green, Antonio Gualberto

    Argitaratua 2009
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  10. 10
    Phase II Study of Sunitinib Malate, an Oral Multitargeted Tyrosine Kinase Inhibitor, in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane

    Phase II Study of Sunitinib Malate, an Oral Multitargeted Tyrosine Kinase Inhibitor, in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane nork Harold J. Burstein, Anthony Elias, Hope S. Rugo, Melody A. Cobleigh, Antonio C. Wolff, Peter D. Eisenberg, Mary Jo Lehman, Bonne J. Adams, Carlo L. Bello, Samuel E. DePrimo, Charles M. Baum, Kathy D. Miller

    Argitaratua 2008
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  11. 11
    Efficacy and Tolerability of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients With Breast Cancer After Moderately Emetogenic Chemotherapy

    Efficacy and Tolerability of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients With Breast Cancer After Moderately Emetogenic Chemotherapy nork David Warr, Paul J. Hesketh, Richard J. Gralla, Hyman B. Muss, Jørn Herrstedt, Peter D. Eisenberg, Harry Raftopoulos, Steven M. Grunberg, Munir Gabriel, Anthony Rodgers, Norman R. Bohidar, George Klinger, Carolyn M. Hustad, Kevin Horgan, Franck Skobieranda

    Argitaratua 2005
    Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  12. 12
    Neurocognitive Function and Progression in Patients With Brain Metastases Treated With Whole-Brain Radiation and Motexafin Gadolinium: Results of a Randomized Phase III Trial

    Neurocognitive Function and Progression in Patients With Brain Metastases Treated With Whole-Brain Radiation and Motexafin Gadolinium: Results of a Randomized Phase III Trial nork Christina A. Meyers, Jennifer A. Smith, Andrea Bezjak, Minesh P. Mehta, James Liebmann, Tim Illidge, Ian Kunkler, J. Caudrelier, Peter D. Eisenberg, J.H. Meerwaldt, Ross Siemers, C. Carrié, Laurie E. Gaspar, Walter J. Curran, S. Phan, Richard Miller, Markus F. Renschler

    Argitaratua 2003
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  13. 13
    Safety, Pharmacokinetics, and Pharmacodynamics of the Insulin-Like Growth Factor Type 1 Receptor Inhibitor Figitumumab (CP-751,871) in Combination with Paclitaxel and Carboplatin

    Safety, Pharmacokinetics, and Pharmacodynamics of the Insulin-Like Growth Factor Type 1 Receptor Inhibitor Figitumumab (CP-751,871) in Combination with Paclitaxel and Carboplatin nork Daniel D. Karp, Michaël Pollak, Roger B. Cohen, Peter D. Eisenberg, Paul Haluska, Donghua Yin, Allan Lipton, Laurence M. Demers, Kim Leitzel, Mary L. Hixon, Leon W.M.M. Terstappen, Linda L. Garland, Luis Paz‐Ares, Felipe Cardenal, Corey J. Langer, Antonio Gualberto

    Argitaratua 2009
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  14. 14
    Phase II and Biomarker Study of the Dual MET/VEGFR2 Inhibitor Foretinib in Patients With Papillary Renal Cell Carcinoma

    Phase II and Biomarker Study of the Dual MET/VEGFR2 Inhibitor Foretinib in Patients With Papillary Renal Cell Carcinoma nork Toni K. Choueiri, Ulka N. Vaishampayan, Jonathan E. Rosenberg, Theodore F. Logan, Andrea Harzstark, Ronald M. Bukowski, Brian I. Rini, Sandy Srinivas, Mark N. Stein, Laurel M. Adams, Lone H. Ottesen, Kevin Laubscher, Laurie Sherman, David F. McDermott, Naomi B. Haas, Keith T. Flaherty, Robert W. Ross, Peter D. Eisenberg, Paul S. Meltzer, Maria J. Merino, Donald P. Bottaro, W. Marston Linehan, Ramaprasad Srinivasan

    Argitaratua 2012
    Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:

Bilaketa egiteko lanabesak: